Wesley Pharma Enters Longevity Market with High-Quality NAD+ Injection

ORLANDO, Fla. – February 11, 2026 – Wesley Pharmaceuticals, a new player in the pharmaceutical outsourcing space, announced today the launch of its NAD+ (Nicotinamide Adenine Dinucleotide) injection, a move that positions the company to capitalize on the rapidly growing longevity and wellness market. The product, previously a flagship offering from its sister brand Olympia Pharmaceuticals, is now being produced at Wesley’s state-of-the-art 503B outsourcing facility, a distinction that carries significant weight in a market under increasing scrutiny.

This strategic launch brings a popular anti-aging formulation under a more rigorous regulatory framework, aiming to provide healthcare providers with a reliable, high-quality source for a treatment sought by a growing number of health-conscious consumers. The new NAD+ is available in a 100mg/mL concentration for intravenous, intramuscular, or subcutaneous administration, signaling the company's intent to become a key supplier for clinics and medical practices nationwide.

The 503B Advantage: A Bet on Quality and Compliance

The most significant aspect of Wesley's launch is its status as a 503B outsourcing facility. Established by the Drug Quality and Security Act, 503B facilities are registered with the U.S. Food and Drug Administration (FDA) and must adhere to Current Good Manufacturing Practice (CGMP) requirements—the same standards that apply to major pharmaceutical manufacturers. This is a stark contrast to traditional 503A compounding pharmacies, which are primarily regulated by state boards and compound drugs based on individual patient prescriptions.

By producing NAD+ in a 503B facility, Wesley Pharmaceuticals can manufacture the drug in bulk for office use without patient-specific prescriptions and distribute it across state lines. This model not only allows for greater scale and market reach but also provides a higher level of quality assurance. The stringent CGMP standards are designed to ensure product sterility, potency, and consistency, addressing common concerns about the quality of compounded medications.

“NAD+ is the gold standard for those pursuing advanced wellness,” said Stan Loomis, co-founder of Olympia and Wesley Pharmaceuticals, in a statement. “By bringing this formulation to Wesley, we are meeting the high demand from our partners and consumers for a product that combines Olympia's exceptional quality with Wesley’s specialized outsourcing standards.”

The move appears to be a direct response to the needs of healthcare providers who require a dependable supply of wellness-focused treatments. Wesley’s commitment to quality is further underscored by its packaging choices, including durable glass vials designed to minimize breakage and enhanced packaging for easier clinical use.

NAD+: Separating Science from Hype

Wesley Pharmaceuticals describes NAD+ as a critical cofactor that enhances mitochondrial function, supports DNA repair, and may improve mental clarity, athletic endurance, and skin tone. As a coenzyme found in all living cells, NAD+ levels are known to decline with age, a fact that has made it a focal point of anti-aging research and marketing. However, the scientific and medical communities urge caution, highlighting a significant gap between preclinical promise and proven human benefits, especially for injectable forms.

Crucially, injectable NAD+ is not an FDA-approved drug for any clinical indication. While the bulk substance is permitted for use in compounding, the final injectable product has not undergone the rigorous, large-scale clinical trials required for FDA approval. The scientific evidence supporting its efficacy for anti-aging, cognitive enhancement, or chronic fatigue in humans remains sparse and limited.

Most human studies on boosting NAD+ levels have focused on oral precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). While these have been shown to safely increase NAD+ levels, research is still ongoing to determine their long-term clinical benefits and optimal dosages. The leap to injectable NAD+, often promoted by wellness clinics for superior bioavailability, is not supported by robust clinical data and introduces a different set of risks.

This places Wesley's launch at the center of a complex dynamic: meeting fervent consumer and provider demand for a promising wellness product while navigating a landscape where definitive scientific validation is still pending.

Regulatory Scrutiny in a High-Demand Market

The market for compounded NAD+ has not been without controversy. The FDA has previously issued warnings to compounders regarding the use of non-pharmaceutical-grade ingredients, which can lead to dangerous levels of endotoxins and other contaminants. Such contamination can cause severe adverse reactions, including fever, shock, and sepsis. In recent years, the industry has seen several recalls of compounded NAD+ injections due to a lack of sterility assurance or elevated endotoxin levels, underscoring the critical importance of quality control.

Against this backdrop, Wesley’s emphasis on its 503B compliance is a powerful marketing tool. By adhering to federal CGMP standards, the company positions itself as a provider of safer, more reliable products in a field where quality can vary dramatically. This commitment to higher standards is a core part of the company's identity.

“Wesley Pharmaceuticals was built on an engineering mindset and finding ways to make great products even better,” stated Naomi Loomis, co-founder of both companies. “Bringing our premier product into the Wesley family allows us to offer our clients more choices and the same trusted quality they expect from our comprehensive wellness ecosystem.”

A Strategic Play for National Reach

The launch is a clear strategic play by the Loomis family, who founded Wesley Pharmaceuticals in 2024 as a sister brand to the established Olympia Pharmaceuticals. The move leverages Olympia's existing client base and product popularity while scaling production and distribution under the more robust 503B framework. Wesley is already licensed in 29 states and has announced plans for further expansion throughout 2026, signaling its ambition for a national footprint.

Furthermore, the company is marketing NAD+ in combination with Sermorelin, a synthetic growth hormone-releasing hormone, to optimize metabolic health. This bundling strategy suggests a broader focus on comprehensive wellness and weight management protocols, tapping into multiple lucrative segments of the health and wellness industry.

By positioning itself as a source of high-quality, compliant, and in-demand compounded medications, Wesley Pharmaceuticals is making a calculated entry into the competitive anti-aging sector. The success of this venture will likely depend not only on its ability to scale production and expand its reach but also on its capacity to build trust with providers who are navigating the delicate balance between patient demand and evidence-based medicine.